title: FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group.
authors.affiliation: Department of Surgery, University of Miami School of Medicine, FL 33101, USA.
authors.forename: J
authors.initials: J
authors.lastname: Miller
authors.forename: J D
authors.initials: JD
authors.lastname: Pirsch
authors.forename: M
authors.initials: M
authors.lastname: Deierhoi
authors.forename: F
authors.initials: F
authors.lastname: Vincenti
authors.forename: R S
authors.initials: RS
authors.lastname: Filo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002648:Child; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000453:epidemiology / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009369:Neoplasms / Q000453:epidemiology; D011183:Postoperative Complications / Q000453:epidemiology; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D016559:Tacrolimus